Cell & Gene: The Podcast 4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D.
Jan 4, 2024
Poseida Therapeutics' CEO Kristin Yarema discusses the challenges of developing off-the-shelf therapies in CGT sector. She highlights the potential progress in allogeneic therapies by 2024. Topics include nanoparticle delivery, allogeneic T cell therapies, strategic investments, manufacturing scale up, and personal plans for 2024.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Allogeneic T Cell Therapies and the Challenges of Scaling
03:23 • 17min
Strategic Investments and Partnerships in Biotech
20:49 • 3min
Manufacturing Scale Up and Cross-Functional Collaboration in Developing Cell Therapy
24:08 • 3min
Personal Plans and Intentions for 2024
27:30 • 4min